Summary
Dominantly acting transforming oncogenes are generally considered to contribute to tumor development and progression by their direct effects on tumor cell proliferation and differentiation. However, the growth of solid tumors beyond 1–2 mm in diameter requires the induction and maintenance of a tumor blood vessel supply, which is attributed in large part to the production of angiogenesis promoting growth factors by tumor cells. The mechanisms which govern the expression of angiogenesis growth factors in tumor cells are largely unknown, but dominantly acting oncogenes may have a much greater impact than hitherto realized. An example of this is the induction of expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by mutant H- or K-ras oncogenes, as well as v-src and v-raf, in transformed fibroblasts or epithelial cells. Besides VEGF/VPF, mutantras genes are known to upregulate the expression of a variety of other growth factors thought to have direct or indirect stimulating effects on angiogenesis, e.g. TGF-β and TGF-α. This effect may be mediated through the ras-raf-MAP kinase signal transduction pathway, resulting in activation of transcription factors such as AP1, which can then bind to relevant sites in the promoter regions of genes encoding angiogenesis growth factors. In principle, similar events could take place after activation or overexpression of many other oncogenes, especially those which can mediate their function through rasdependent signal transduction pathways. The regulatory effect of oncogenes on mediators of angiogenesis has some potentially important therapeutic consequences. For example, it strengthens the rationale of pharmacologically targeting oncogene products, such as mutant RAS proteins, as an anti-tumor therapeutic strategy. Such drugs may attack the source of one or more angiogenic growth factors and by doing so, function, at least in part, as anti-angiogenic agents in vivo.
Similar content being viewed by others
References
Barbacid M: ras genes. Ann Rev Biochem 56: 779–827, 1987
Pronk GJ, Bos JL: The role of p21ras in receptor tyrosine signalling. Biochim Biophys Acta 1198: 131–147, 1994
Khosravi-Far R, Der CJ: The Ras signal transduction pathway. Cancer Metastasis Rev in press: 1995
Buick RN, Filmus J, Quaroni A: Activated H-ras transforms rat intestinal epithelial cells with expression of α-TGF. Exp Cell Res 170: 300–309, 1987
Filmus J, Robles AL, Shi W, Wong MJ, Colombo LL, Conti CJ: Induction of cyclin D1 overexpression by activatedras. Oncogene 9: 3726–3633, 1994
Bischop M: Molecular themes in oncogenesis. Cell 64: 235–248, 1991
Folkman J: What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82: 4–6, 1990
Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1: 149–153, 1995
Rak JN, St. Croix B, Kerbel RS: Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs 6: 3–18, 1995
Thompson TC, Southgate J, Kitchener G, Land H: Multistage carcinogenesis induced byras andmyc oncogenes in a reconstituted organ. Cell 56: 917–930, 1989
Sugihara T, Kaul SC, Mitsui Y, Wadhwa R: Enhanced expression of multiple forms of VEGF is associated with spontaneous immortalization of murine fibroblasts. Biochim Biophys Acta 1224: 365–370, 1994
Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature 339: 58–61, 1989
Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66: 1095–1104, 1991
Rak J, Mitsuhashi Y, Bayko L, Filmus J, Sasazuki T, Kerbel RS: Mutantras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575–4580, 1995
Grugel S, Finkenzeller G, Weindel K, Barleon B, Marmé D: Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 270: 25915–25919, 1995
Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798–1801, 1992
Hu DE, Hory Y, Fan TP: Interleukin-8 stimulates angiogenesis in rats. Inflammation 17: 135–143, 1993
Petzelbauer P, Watson CA, Pfau SE, Pober JS: IL-8 and angiogenesis: evidence that human endothelial cells lack receptors and do not respond to IL-8in vitro. Cytokine 7: 267–272, 1995
Baird A, Durkin T: Inhibition of endothelial cell proliferation by type-beta transforming growth factor: interactions with acidic and basic fibroblast growth factors. Biochem Biophys Res Commun 138: 476–482, 1986
Frater-Schroder M, Muller G, Birchmeier W, Bohlen P: Transforming growth factor beta inhibits endothelial cell proliferation. Biochem Biophys Res Commun 137: 295–302, 1986
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, Fauci AS: Transforming growth factor type beta: rapid induction of fibrosis and angiogenesisin vivo and stimulation of collagen formationin vitro. Proc Natl Acad Sci (USA) 83: 4167–4171, 1986
Risau W: Differentiation of endothelium. FASEB J 9: 926, 1995
Senger DR, Perruzzi CA, Feder J, Dvorak HG: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46: 5629–5632, 1986
Senger DR, Connolly D, Perruzzi CA, Alsup D, Nelson R, Leimgruber R, Feder J, Dvorak HF: Purification of a vascular permeability factor (VPF) from tumor cell conditioned medium. Fed Proc 46: 2102, 1987
Dvorak HF, Brown LF, Detmar M, Dvorak AM: Review: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029–1039, 1995
Kolch W, Martiny-Baron G, Kieser A, Marmé D: Regulation of the expression of VEGF/VPF and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat 36: 139–155, 1995
Klagsbrun M, Soker S: VEGF/VPF: the angiogenesis factor found? Curr Biol 3: 699–702, 1993
Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36: 127–137, 1995
Mustonen T, Alitalo K: Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129: 895–898, 1995
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growthin vivo. Nature 362: 841–844, 1993
Warren RS, Yuan H, Mati MR, Gillett NA, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789–1797, 1995
Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibitedin vivo by a dominant-negative Flk-1 mutant. Nature 367: 576–579, 1994
Toi M, Inada K, Suzuki H, Tominage T: Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36: 193–204, 1995
Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845, 1992
Mukhopadhyay D, Tsiokas L, Zhou X-M, Foster D, Brugge JS, Sukhatme VP: Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375: 577–581, 1995
Stein I, Neeman M, Shweiki D, Itin A, Keshet E: Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemiainduced genes. Mol Cell Biol 15: 5363–5368, 1995
Kieser A, Weich HA, Brandner G, Marmé D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9: 363–369, 1994
Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. J Biol Chem 266: 11947–11954, 1991
Finkenzeller G, Technau A, Marmé D: Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor. Biochem Biophys Res Commun 208: 432–439, 1995
Jamal H, Cano-gauci DF, Buick RN, Filmus J: Activatedras andsrc induce CD44 overexpression in rat intestinal epithelial cells. Oncogene 9: 417–423, 1994
Shirasawa S, Furuse M, Yokoyama N, Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85–88, 1993
Vukicevic S, Kleinman HK, Luyten FP, Roberts AB, Roche NS, Reddi AH: Identification of multiple active growth factors in basement membrane matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res 202: 1–8, 1992
Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, Mulshine JL: Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci (USA) 87: 6698–6702, 1990
Kibbey MC, Grant DS, Kleinman HK: Role of the SIKVAV site of laminin in promotion of angiogenesis and tumor growth: anin vivo matrigel model. J Natl Canc Inst 84: 1633–1638, 1992
Kobayashi H, Man S, MacDougall JR, Graham CH, Lu C, Kerbel RS: Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine resistant phenotype. Am J Pathol 144: 776–786, 1994
Bonfil RD, Vinyals A, Bustuoabad OD, Llorens A, Benavides FJ, Gonzales-Garrigues M, Fabra A: Stimulation of angiogenesis as an explanation of Matrigel-enhanced tumorigenicity. Int J Cancer 58: 233–239, 1994
Klein G: Multistep emancipation of tumors from growth control: can it be cured in a single step? BioEssays 12: 347–351, 1990
Dameron KM, Volpert OV, Tainsky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582–1584, 1994
Van Meir EG, Polverini PJ, Chazin VR, Huang SH-J, Tribolet N, Cavanee WK: Release of an inhibitor of angiogenesis upon induction of wild typep53 expression in glioblastoma cells. Nature Genetics 8: 171–182, 1994
Huang H-JS, Yee J-K, Shew J-Y, Chen P-L, Bookstein R, Friedmann T, Lee EY-HP, Lee W-H: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242: 1563–1566, 1988
Bookstein R, Shew J-Y, Chen P-L, Scully P, Lee W-H: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutatedRB gene. Science 247: 712, 1995
Iliopoulos O, Kibel A, Gray S, Kaelin Jr WG: Tumour suppression by the human von Hippel-Lindau gene product. Nature Medicine 1: 822, 1995
Wizigmann-Voos S, Breier G, Risau W, Plate KH: Up-regulation of vascular endothelial growth factor andits receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358–1364, 1995
Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Medicine 1: 1024–1028, 1995
Strawhecker JM, Pelling JC: Inhibition of mouse skin tumorigenesis by dexamethasone occurs through a Ha-ras-independent mechanism. Carcinogenesis 13: 2075–2080, 1992
Lee K, Iwamura M, Crockett ATK: Cortisone inhibition of tumor angiogenesis measured by a quantitative colorimetric assay in mice. Cancer Chemoth Pharm 26: 461–463, 1990
Lee K, Erturk E, Mayer R, Cockett ATK: Efficacy of antitumor chemotherapy in C3H mice enhanced by the antiangiogenesis steroid, cortisone acetate. Cancer Res 47: 5021–5024, 1987
Kerppola TK, Luk D, Curran T: Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity in vitro. Mol Cell Biol 13: 3782–3791, 1993
Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, Spiegelman BM: c-fos is required for malignant progression for skin tumors. Cell 82: 721–732, 1995
Anzano M, Roberts A, Delarco J, Wakefield L, Assoian R, Roche N, Smith J, Lazarus J, Sporn M: Increased secretion of type beta transforming growth factor accompanies viral transformation of cells. Mol Cell Biol 5: 242–247, 1985
Pertovaara L, Kaipanen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K: Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 269: 6271–6274, 1994
Detmar M, Brown LF, Claffey KP, Kiang-Teck Y, Kocher O, Jackman RW, Berse B, Dvorak HFL Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180: 1141–1146, 1994
Pepper MS, Ferrara N, Orci L, Montesano R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesisin vitro. Biochem Biophys Res Commun 189: 824–831, 1992
Goto F, Goto K, Weindel K, Folkman J: Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 69: 508, 1993
Toi M, Inada K, Hoshima S, Suzuki H, Kondo S, Tominaga T: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1: 961–964, 1995
Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759–767, 1990
Galand P, Jacobovitz D, Alexandre K: Immunohistochemical detection of c-Ha-ras oncogene p21 product in pre-neoplastic and neoplastic lesions during hepatocarcinogenesis in rats. Int J Cancer 41: 155–161, 1995
Hasegawa H, Ueda M, Watanabe M, Teramoto T, Mukai M, Kitajima M: K-ras gene mutations in early colorectal cancer... flat elevated vs polyp-forming cancer... Oncogene 10: 1413–1416, 1995
Minamoto T, Sawaguchi K, Mai M, Yamashita N, Sugimura T, Esumi H: Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. Cancer Res 54: 2841–2844, 1994
Rak J, Mituhashi Y, Erdos V, Huang S-N, Filmus J, Kerbel RS: Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogenes. J Cell Biol in press: 1995
Berse B, Brown LF, Van De Water L, Dvorak HF, Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3: 211–220, 1992
Ohta Y, Tone T, Shitara T, Funato T, Jiao L, Kashfian BI, Yoshida E, Horng M, Tsai P, Lauterbach K, Kashani-Sabet M, Florenes VA, Fodstad O: H-ras ribozyme-mediated alteration of the human melanoma phenotype. Gene Therapy Neopl Dis 716: 242, 1994
Kashani-Sabet M, Funato T, Tone T, Jiao L, Wang W, Yoshida E, Kashfinn BI, Shitara T, Wu AM, Moreno JG, Traweek ST, Ahlering TE, Scanlon KJ: Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev 2: 3–15, 1992
Ferrari G, Greene LA: Proliferative inhibition by dominant-negative Ras rescues naive and neuronally differentiated PC12 cells from apoptotic death. EMBO J 13: 5922–5928, 1994
Sakai N, Ogiso Y, Fujita H, Watari H, Koike T, Kuzumaki N: Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells. Exp Cell Res 215: 131–136, 1994
James GL, Goldstein JL, Brown MS: Polylysine and DVIM sequences of K-rasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimeticin vitro. J Biol Chem 270: 6221–6226, 1995
Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition ofras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934–1942, 1993
Gibbs JB, Oliff A, Kohl NE: Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 77: 175–178, 1994
Lowry DR, Willumsen BM: Rational cancer therapy. Nature Medicine 1: 747–748, 1995
Kiaris H, Spandidos DA: Mutations ofras genes in human tumours. Int J Oncol 7: 413–421, 1995
Kohl NE, Wilson FR, Mossier SD, Giuliani E, deSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A: Protein farnesyltransferase inhibitors block the growth ofras-independent tumors in nude mice. Proc Natl Acad Sci (USA) 91: 9141–9145, 1994
Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, Hartman GD, Koblan KS, Kral AM, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Gibbs JB, Oliff A: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas inras transgenic mice. Nature Medicine 1: 792–797, 1995
Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci (USA) 92: 4562–4566, 1995
Burrows FJ, Thorpe PE: Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci (USA) 90: 8996–9000, 1993
Bouck N: Tumor angiogenesis: the role of oncogenes and tumor suppressor genes. Cancer Cells 2: 179–185, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rak, J., Filmus, J., Finkenzeller, G. et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metast Rev 14, 263–277 (1995). https://doi.org/10.1007/BF00690598
Issue Date:
DOI: https://doi.org/10.1007/BF00690598